New York, January 16, 2014 -- Moody's Investors Service said that yesterday's announcement that a jury in the Federal District Court of Delaware ruled that Medtronic, Inc.'s (A2 stable) CoreValve transcatheter heart valve (THV) system infringes on Edwards Lifesciences Corporation's (Baa3 stable) Cribier patent, is credit negative for Medtronic and credit positive for Edwards. At this time, however, this development has no impact on either company's ratings or outlooks. For additional information, please see Moody's Issuer Comment on Medtronic and Edwards on www.moodys.com.

Vollständigen Artikel bei Moodys lesen